-
(1S,5R,13R,17S)-10,17-dihydroxy-4-(prop-2-en-1-yl)-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one
-
ChemBase ID:
1054
-
Molecular Formular:
C19H21NO4
-
Molecular Mass:
327.37434
-
Monoisotopic Mass:
327.14705816
-
SMILES and InChIs
SMILES:
O1[C@@H]2[C@]34[C@](O)([C@H](N(CC3)CC=C)Cc3c4c1c(O)cc3)CCC2=O
Canonical SMILES:
C=CCN1CC[C@@]23[C@@]4([C@H]1Cc1c3c(O[C@H]2C(=O)CC4)c(cc1)O)O
InChI:
InChI=1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1
InChIKey:
UZHSEJADLWPNLE-GRGSLBFTSA-N
-
Cite this record
CBID:1054 http://www.chembase.cn/molecule-1054.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
(1S,5R,13R,17S)-10,17-dihydroxy-4-(prop-2-en-1-yl)-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one
|
|
|
IUPAC Traditional name
|
|
Brand Name
|
Nalone
|
Narcan
|
Narcanti
|
Narcon
|
|
|
Synonyms
|
L-Naloxone
|
N-Allylnoroxymorphone
|
EN 1530 Base
|
Nalossone [Dcit]
|
Naloxona [INN-Spanish]
|
Naloxone HCl
|
Naloxonum [INN-Latin]
|
Naloxone
|
|
|
CAS Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
Data Source
|
Data ID
|
Price
|
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
ALOGPS 2.1
Acid pKa
|
10.066371
|
H Acceptors
|
5
|
H Donor
|
2
|
LogD (pH = 5.5)
|
-0.6951441
|
LogD (pH = 7.4)
|
1.0430377
|
Log P
|
1.6202211
|
Molar Refractivity
|
88.7222 cm3
|
Polarizability
|
34.542297 Å3
|
Polar Surface Area
|
70.0 Å2
|
Rotatable Bonds
|
2
|
Lipinski's Rule of Five
|
true
|
Log P
|
1.47
|
LOG S
|
-1.76
|
Solubility (Water)
|
5.64e+00 g/l
|
PROPERTIES
PROPERTIES
Physical Property
Bioassay(PubChem)
Solubility
|
Soluble
|
Show
data source
|
|
Hydrophobicity(logP)
|
0.6
|
Show
data source
|
|
DETAILS
DETAILS
DrugBank
DrugBank -
DB01183
|
Item |
Information |
Drug Groups
|
approved |
Description
|
A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. [PubChem] |
Indication |
For the complete or partial reversal of narcotic depression, including respiratory depression, induced by opioids including natural and synthetic narcotics, propoxyphene, methadone and the narcotic-antagonist analgesics: nalbuphine, pentazocine and butorphanol. |
Pharmacology |
Naloxone is an opiate antagonist and prevents or reverses the effects of opioids including respiratory depression, sedation and hypotension. Also, it can reverse the psychotomimetic and dysphoric effects of agonist-antagonists such as pentazocine. Naloxone is an essentially pure narcotic antagonist, i.e., it does not possess the "agonistic" or morphine-like properties characteristic of other narcotic antagonists; naloxone does not produce respiratory depression, psychotomimetic effects or pupillary constriction. In the absence of narcotics or agonistic effects of other narcotic antagonists, it exhibits essentially no pharmacologic activity. |
Affected Organisms |
• |
Humans and other mammals |
|
Biotransformation |
Hepatic. |
Absorption |
Well absorbed following intramuscular injection. |
Half Life |
30-81 minutes |
External Links |
|
|
PATENTS
PATENTS
PubChem Patent
Google Patent